Answers are grounded in this paper and cite their sources.
Toxoplasma gondii is a highly successful apicomplexan protozoan capable of infecting any warm-blooded animal worldwide. In humans, Toxoplasma infections are life-long, with approximately one-third of the world's population chronically infected. Although normally controlled by the host immune system, T. gondii infection can lead to a variety of clinical outcomes in individuals with immature or suppressed immune systems. After penetrating the intestine, parasites rapidly disseminate throughout the body and stimulate production of the cytokines interleukin (IL)-12, IL-18, and interferon (IFN)-γ by immune cells. These cytokines play a key role in host resistance to T. gondii by promoting a strong Th1 response. Recent reports show that gut commensal bacteria can act as molecular adjuvants during T. gondii infection. Thus, T. gondii is an excellent model system to study host-pathogen interactions. This unit outlines the protocols for in vitro and in vivo maintenance and growth of T. gondii.
No takes yet. Share an insight, caveat, or question.
Khan et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: